Suzhou Kang'er Biopharmaceutical

Keythera Biopharmaceuticals is a clinical-stage biotechnology company based in Suzhou, China, specializing in the discovery and development of innovative small molecule therapeutics. The company utilizes its proprietary Affinity Detection by Mass Spectroscopy (ADMS) platform, an intelligent high-throughput screening technology that integrates bioinformatics and AI to expedite drug discovery. Keythera's lead program, KF-0210, is a highly selective EP4 receptor antagonist currently in Phase 2 clinical trials for osteoarthritis and Phase 1b for various solid tumors. Its pipeline also includes KBP-2205, a second-generation PARP1 inhibitor, and KBP-2506, an MRGPRX2 antagonist for inflammatory skin diseases. The company focuses on addressing significant unmet needs in oncology, autoimmune diseases, and chronic inflammatory conditions.